Haselnuss Hal Allergy (Hazelnut)

Haselnuss Hal Allergy is a diagnostic allergen product containing hazelnut extract, supplied in a cutaneous testing format. It is intended for use in the European market to support the identification of IgE-mediated hypersensitivity to hazelnut. The preparation is applied to the skin during allergy testing and is not a therapeutic medication. The product is packaged in a sealed vial for application and complies with EU regulatory standards for diagnostic allergens.

Haselnuss Hal Allergy is employed primarily as a diagnostic tool to assess sensitization to hazelnut in patients suspected of having a food allergy.

- Skin prick testing to detect immediate‑type hypersensitivity to hazelnut. - Confirmation of hazelnut allergy when clinical history is unclear. - Differentiation of hazelnut allergy from other tree‑nut sensitivities. - Guidance for dietary management and avoidance strategies. - Support for clinicians in allergy clinics and specialist centers.

Skin testing with hazelnut extract may cause local reactions; most are mild and transient, while rare systemic responses can occur.

Common: - Redness at the test site. - Small swelling or wheal formation. - Itching or mild discomfort. - Minor hives limited to the area of application.

Serious: - Large wheal or flare extending beyond the test site. - Systemic urticaria. - Respiratory symptoms such as wheezing or shortness of breath. - Anaphylaxis (rare but requires immediate medical attention).

When using Haselnuss Hal Allergy, clinicians should observe several safety measures to minimize risk.

- Verify that the patient has no history of severe anaphylaxis to hazelnut before testing. - Avoid testing on broken, inflamed, or infected skin. - Ensure emergency equipment (e.g., epinephrine) is readily available. - Use the product under the supervision of trained healthcare personnel. - Consider age‑related guidelines; pediatric testing may require adjusted protocols. - Document any prior antihistamine or medication use that could affect results.

Certain medications and conditions can influence the outcome of hazelnut skin testing or increase risk.

Avoid: - Antihistamines or other mast cell stabilizers taken within 48–72 hours, as they may suppress skin reactivity. - Recent systemic corticosteroids that could diminish test responses.

Use with caution: - Beta‑blockers, which may interfere with treatment of severe reactions. - Ongoing allergen immunotherapy, which could alter skin test sensitivity. - ACE inhibitors, due to potential enhancement of angioedema. - Patients with uncontrolled asthma, requiring careful monitoring during testing.